%0 Journal Article %A Zoe L. Lyski %A Amanda E. Brunton %A Matt I. Strnad %A Peter E. Sullivan %A Sarah A.R. Siegel %A Fikadu G. Tafesse %A Mark K. Slifka %A William B. Messer %T SARS-CoV-2 specific memory B-cells from individuals with diverse disease severities recognize SARS-CoV-2 variants of concern %D 2021 %R 10.1101/2021.05.28.21258025 %J medRxiv %P 2021.05.28.21258025 %X In this investigation we examined the magnitude, breadth, and durability of SARS-CoV-2 specific antibodies in two distinct B-cell compartments: long-lived plasma cell-derived antibodies in the plasma, and peripheral memory B-cells along with their associated antibody profiles elicited after in vitro stimulation. We found that magnitude varied amongst individuals, but was the highest in hospitalized subjects. Variants of concern (VoC) -RBD-reactive antibodies were found in the plasma of 72% of samples in this investigation, and VoC-RBD-reactive memory B-cells were found in all but 1 subject at a single time-point. This finding, that VoC-RBD-reactive MBCs are present in the peripheral blood of all subjects including those that experienced asymptomatic or mild disease, provides a reason for optimism regarding the capacity of vaccination, prior infection, and/or both, to limit disease severity and transmission of variants of concern as they continue to arise and circulate.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by federal funds from the National Institute of Allergy and Infectious Diseases NIAID 1R01AI145835 (WBM), by the Oregon National Primate Research Center grant, 8P51 OD011092 (MKS) and a pilot project grant from the OHSU Foundation (MKS), and Oregon Health & Science University Innovative IDEA grant 1018784 (FGT).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by the Oregon Health & Science University Institutional Review Board (IRB# 21230). Informed consent was obtained from subjects on initiation of their participation in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo additional data or external datasets %U https://www.medrxiv.org/content/medrxiv/early/2021/06/03/2021.05.28.21258025.full.pdf